Key result
Simultaneous administration of the HRA2 peptide and a lethal hMPV challenge completely protected mice from mortality and resulted in undetectable lung viral loads compared to 30,000 TCID50/lung in untreated mice.
Why the study?
Does HRA2 peptide prevent mortality and reduce viral load in hMPV-infected BALB/c mice?
Population
BALB/c mice and in vitro models
Comparison
HRA2 peptide vs Untreated mice
Design
Preclinical
Follow-up
5 days postinfection
Authors
Loading...
HRA2 merits further preclinical development for hMPV; hypothesis-generating in mice and leaves open human translation.
Does HRA2 peptide prevent mortality and reduce viral load in hMPV-infected BALB/c mice?
p-value: p=<0.05
The HRA2 peptide demonstrates potent antiviral activity against human metapneumovirus, completely protecting mice from lethal challenge and reducing viral load and inflammation.
Deffrasnes et al. (2007) studied Human metapneumovirus (hMPV) infection (n=90). HRA2 peptide vs. Untreated (hMPV only) or HRB1 control peptide was evaluated on Lung viral load at day 5 postinfection (p=<0.05). Simultaneous administration of the HRA2 peptide and a lethal hMPV challenge completely protected mice from mortality and resulted in undetectable lung viral loads compared to 30,000 TCID50/lung in untreated mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: